Leben mit pulmonaler Hypertonie

Literatur

• 1 Rubin L J. Current concepts: primary pulmonary hypertension.  N Engl J Med. 1997;  336 111-117
• 2 Olschewski H, Olschewski A, Rose F. et al . Physiologic basis for the treatment of pulmonary hypertension.  J Lab Clin Med. 2001;  138 287-297
• 3 Olschewski H, Rose F. et al . Cellular pathophysiology and therapy of pulmonary hypertension.  J Lab Clin Med. 2001;  138 367-377
• 4 Deng Z, Morse J H, Slager S L. et al . Familial primary pulmonal hypertension is caused by mutations in the bone morphogenetic proteine receptor-II gene.  Am J Hum Genet. 2000;  67 737-744
• 5 Machado R D, Pauciulo M W, Thomson J R. et al . BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.  Am J Hum Genet. 2001;  68 92-102
• 6 Olschewski H, Ghofrani A, Wiedemann R. et al . Pulmonaler Hochdruck.  Internist. 2002;  43 1498-1509
• 7 Sitbon O, Humbert M, Jagot J L. et al . Inhaled nitric oxide as a screening agent for safely identifying responders to oral calciumchannel blockers in primary pulmonary hypertension.  Eur Respir J. 1998;  12 265-270
• 8 Higenbottam T, Wheeldon D, Wells F. et al . Long-term treatment of primary pulmonary hypertension with continous intravenous epoprostenol (prostacyclin).  Lancet. 1984;  1 1046-1047
• 9 Hoeper M M, Olschewski H, Ghofrani H A. et al . A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group.  J Am Coll Cardiol. 2000;  35 176-182
• 10 Channick R N, Simmonneau G, Sitbon O. et al . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension.  Lancet. 2001;  358 1119-1123